Videos

Preventing progression from prediabetes to type 2 diabetes improves patient outcomes while substantially reducing health system greenhouse gas emissions.

Finibrutinib’s phase 3 MS results hint at new hope for relapsing and progressive disease, as experts weigh safety and monitoring.

Why MS relapses aren’t the whole story: experts explain PIRA, the push for remyelination, and how BTK inhibitors may reach the CNS.

TrumpRx offers select branded drugs at cash prices outside insurance, requiring pharmacists to guide patients on cost comparisons, coverage limitations, and safe medication management, according to Ronna Hauser, PharmD.

Anne Cassity details the National Community Pharmacists Association's (NCPA's) next pharmacy benefit manager (PBM) reform priorities, focusing on fair pharmacy reimbursement and congressional scrutiny of health care consolidation and vertical integration.

Allison Hill, PharmD, RPh, underscores how pharmacists can sustain vaccination momentum through community partnerships.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Counseling Patients With oHCM – Using Data to Instill Confidence

Treatment Options for oHCM – Aligning Guidance With Real-World Data to Improve Outcomes

Pharmacists enhance pneumococcal vaccination integration through routine screenings, flexible access, and team-based approaches for improved patient care.

Anne Cassity explains how Medicare Part D’s move to flat PBM service fees in 2028 may reduce incentives for high-cost formulary placement and support more cost-conscious medication decisions.

Allison Hill, PharmD, RPh, emphasizes that it is not too late for flu vaccination and highlights how pharmacists can address vaccine fatigue.

Collaborative practice agreements let pharmacists speed multiple sclerosis therapy starts, manage labs, and boost adherence—easing provider workload.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.

Anne Cassity of the NCPA outlines the historic passage of federal pharmacy benefit manager (PBM) reform and explains how new Medicare Part D contracting standards could reshape reimbursement and oversight for community pharmacies.

MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemo use while protecting outcomes.

MS experts say MRI and current trial endpoints miss “smoldering” progression; emerging biomarkers, 7T imaging, PROs, and CNS-penetrant therapies aim to close gaps.

Learn how hidden neuroinflammation drives MS progression, why MRI may miss it, and how rim lesions and testing track disability.

Pharmacists are central to optimizing chronic kidney disease (CKD) diagnosis and monitoring long-term adherence to disease-modifying therapies.

Pharmacists can use collaborative practice agreements in neurology to manage multiple sclerosis medications, labs, and expand care beyond disease-modifying therapies.

Oncology pharmacists use MammaPrint to target anthracyclines in high-risk breast cancer, sparing others cardiotoxicity and severe nausea.

In this closing episode, the panel outlines practical steps pharmacists can take to support ongoing tardive dyskinesia monitoring across the care continuum.

Explore the exciting advancements in hemophilia therapies, emphasizing personalized care and the vital role of pharmacists in patient treatment.

Pharmacists are critical in supporting GLP-1 therapy success through proactive expectation setting.

Sarah Nelson, PharmD, explains how pharmacists can simplify cardiovascular treatment regimens through personalized education, shared decision-making, and cross-sector collaboration to improve adherence and close care gaps in heart disease prevention.

Pharmacists enhance patient trust by addressing concerns, providing evidence-based guidance, and promoting vaccination through clear communication and follow-ups.

Learn how diffuse neuroinflammation drives progressive MS, how MRI finds paramagnetic rim lesions, and which cognitive and physical tests track disability over time.

Learn how MRI, OCT, and CSF markers refine MS diagnosis and monitoring, and why “active” disease matters beyond relapses.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

The VESALIUS-CV trial demonstrates that adding evolocumab to maximally tolerated statin therapy significantly reduces major cardiovascular events in both high-risk primary and secondary prevention patients.